Up to 12 Months of Efficacy and Safety of Elagolix Treatment in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids

医学 月经出血 子宫肌瘤 子宫出血 月经 产科 妇科 内科学
作者
WD Schlaff,Veronica Gillispie,Jhj Kim,Charlotte D. Owens,R Liu,Ozgul Muneyyirci-Delale
出处
期刊:Journal of Minimally Invasive Gynecology [Elsevier]
卷期号:26 (7): S66-S67
标识
DOI:10.1016/j.jmig.2019.09.665
摘要

Study Objective To evaluate the efficacy and safety of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in women with heavy menstrual bleeding (HMB) associated with uterine fibroids (UF) for up to 12-months. Design Elaris UF-EXTEND, a phase 3 extension study of two pivotal 6-month phase 3 studies, Elaris UF-1 and UF-2, evaluated the efficacy and safety of an additional 6-months of treatment (up to 12-months total) with elagolix 300mg twice daily (BID) with add-back therapy (1mg estradiol/0.5mg norethindrone acetate [E2/NETA] once daily) and elagolix 300mg BID alone as a reference arm. Setting Outpatient setting. Patients or Participants Participants were premenopausal women age 18-51 with HMB (>80mL/cycle menstrual blood loss [MBL]) associated with UF. A total of 433 women who completed the 6-month treatment period in the pivotal studies were enrolled in Elaris UF-EXTEND. Interventions Women who received elagolix+E2/NETA or elagolix alone in the pivotal studies continued to receive the same treatment while women who received placebo were randomized 1:1 to receive one of the two elagolix treatments. Here, we report data from women who received elagolix+E2/NETA or elagolix alone in both pivotal and extension studies. Measurements and Main Results MBL was assessed by the alkaline hematin method. Baseline was defined as the measure obtained before dosing in pivotal studies. 87.9% of women who received elagolix+E2/NETA and 89.4% who received elagolix alone had Conclusion Treatment with elagolix+E2/NETA for up to 12-months provided sustained MBL reduction comparable to elagolix alone with a safety profile consistent with preceding pivotal studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
慕青应助富贵采纳,获得10
1秒前
2秒前
3秒前
SUPERDOUBLE完成签到,获得积分10
4秒前
芜湖芜湖发布了新的文献求助10
5秒前
LX-ik完成签到,获得积分10
5秒前
mbf发布了新的文献求助10
6秒前
7秒前
7秒前
美满广缘发布了新的文献求助10
9秒前
LX-ik发布了新的文献求助10
10秒前
烟花应助芜湖芜湖采纳,获得10
11秒前
12秒前
爱静静应助wang5945采纳,获得10
13秒前
就先这样吧完成签到,获得积分10
15秒前
15秒前
若朴祭司发布了新的文献求助30
15秒前
完美世界应助无敌最俊朗采纳,获得10
20秒前
21秒前
迷人不凡发布了新的文献求助10
21秒前
22秒前
26秒前
共享精神应助痴情的靖柔采纳,获得30
28秒前
28秒前
Jun发布了新的文献求助10
29秒前
30秒前
31秒前
田様应助mbf采纳,获得10
31秒前
富贵发布了新的文献求助10
32秒前
33秒前
33秒前
35秒前
简单的老九完成签到 ,获得积分10
35秒前
搞怪人杰发布了新的文献求助10
36秒前
keyine完成签到,获得积分10
38秒前
39秒前
戴呆发布了新的文献求助150
40秒前
Fa发布了新的文献求助10
40秒前
43秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 600
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3153361
求助须知:如何正确求助?哪些是违规求助? 2804608
关于积分的说明 7860306
捐赠科研通 2462547
什么是DOI,文献DOI怎么找? 1310806
科研通“疑难数据库(出版商)”最低求助积分说明 629396
版权声明 601794